NCT05965089View on ClinicalTrials.gov

A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions

Healthy VolunteersMild to Moderate Psoriasis

Interventions

BIOLOGICAL

Placebo

Placebo

BIOLOGICAL

AX-202

Humanized monoclonal antibody

Trial Locations (1)

M23 9QZ

Medicines Evaluation Unit, Manchester

Sponsors

Lead Sponsor

Arxx Therapeutics

All Listed Sponsors

lead

Arxx Therapeutics

INDUSTRY

NCT05965089 - A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis. | Biotech Hunter | Biotech Hunter